Keratinizing
Epithelial
Cells
keratinocyte of epidermis (= differentiating epidermal cell) basal cell of epidermis (stem cell) keratinocyte of fingernails and toenails basal cell of nail bed (stem cell) hair shaft cells medullary
cortical cuticular
hair-root sheath cells cuticular of
Huxley's layer of Henle's layer external hair
matrix cell (stem cell)
Cells of Wet Stratified Barrier Epithelia
surface epithelial cell of
stratified squamous epithelium of comea, tongue, oral cavity, esophagus, anal
canal, distal urethra, vagina basal cell of these epithelia (stem cell) cell of
urinary epithelium (lining bladder and urinary
ducts)
Epithelial Cells
Specialized for Exocrine
Secretion
cells of salivary gland
mucous cell (secretion rich in polysaccharide)
serous cell (secretion rich in glycoprotein
enzymes) cell
of von Ebner's gland in tongue (secretion to
wash over taste buds) cell of mammary gland, secreting milk cell of lacrimal gland, secreting tears cell of ceruminous gland of ear, secreting wax cell of eccrine sweat gland, secreting glycoproteins (dark cell) cell of eccrine sweat gland, secreting small molecules
(clear cell) cell of apocrine sweat
gland (odoriferous secretion, sex-hormone sensitive) cell of gland of Moll in eyelid (specialized sweat gland) cell
of sebaceous gland, secreting lipid-rich sebum
cell of Bowman's gland in nose (secretion
to wash
over olfactory epithelium) cell of Brunner's
gland in duodenum, secreting alkaline
solution of mucus and enzymes cell of seminal vesicle, secreting components of seminal
fluid, including fructose ias fuel for
swimming
sperm) cell of prostate gland,
secreting other components of seminal fluid
cell of bulbourethral gland, secreting
mucus cell of Bartholin's gland, secreting
vaginal lubricant cell
of gland of Littre, secreting mucus cell
of endometrium of uterus, secreting mainly carbohydrates isolated goblet cell of respiratory and digestive tracts, secreting mucus mucous cell of lining of stomach zymogenic cell of
gastric gland, secreting pepsinogen oxyntic cell of gastric gland, secreting HC1 acinar cell of pancreas, secreting digestive enzymes and bicarbonate Paneth cell of small intestine, secreting lysozyme type II pneumocyte of
lung, secreting surfactant Clara cell of lung (function unknown)
Cells Specialized for Secretion of Hormones
cells of anterior pituitary, secreting growth hormone follicle-stimulating hormone
luteinizing
hormone prolactin
adrenocorticotropic hormone thyroid-stimulating hormone cell of intermediate pituitary, secreting melanocyte-stimulating hormone cells of posterior pitutiary, secreting oxytocin vasopressin
cells of gut and respiratory tract, secreting serotonin endorphin somatostatin gastrin
secretin cholecystokinin insulin glucagons bombesin cells
of thyroid gland, secreting thyroid hormone
calcitonin
cells of parathyroid gland, secreting parathyroid hormone oxyphil
cell (function unknown) cells of adrenal
gland, secreting epinephrine norepinephrine,
steroid hormones mineralocorticoids glucocorticoids cells
of gonads, secreting testosterone (Leydigc
ell
of testis) estrogen (theca interna
cell of ovarian follicle) progesterone (corpus luteum cell of ruptured ovarian
follicle) cells of juxtaglomerular
apparatus of kidney juxtaglomerular cell
(secreting renin) . Uncertain
but macula densa, probably related
cell in function; peripolar cell possibly
involved mesangial cell in
secretion of erythropoietin).
Epithelial Absorptive
Cells in Gut, Exocrine Glands, and Urogenital Tract
brush border cell of intestine (with microvilli) striated
duct cell of exocrine glands gall bladder epithelial cell brush border cell of
proximal tubule of kidney distal
tubule cell of kidney nonciliated cell
of ductulus efferens epididymal principal
cell epididymal basal cell
Cells Specialized for Metabolism and Storage
hepatocyte (liver cell) fat cells white fat brown fat lipocyte of liver.
Epithelial Cells Serving
Primarily a Barrier Function, Lining the Lung, Gut, Exocrine Glands, and Urogenital
Tract
Type I pneumocyte (lining air space
of lung) pancreatic
duct cell (centroacinar cell) nonstriated duct cell of sweat gland, salivary
gland, mammary gland, etc. (various) parietal cell of kidney glomerulus podocyte of kidney glomerulus cell of thin segment of loop of Henle
(in kidney) collecting duct cell (in kidney) duct cell of seminal vesicle,
prostate gland, etc.
(various).
Epithelial Cells
Lining Closed Internal Body Cavities
vascular endothelial cells
of blood vessels and lymphatics.
1188 Chapter
22 :
Differentiated Cells and the Maintenance of Tissues
Table 24-1
Cancer Incidence and Cancer Mortality in the United States, 1993
Type of
Cancer
New Cases per Year
|
Deaths per
Year
|
Total cancers
|
1,170,00
|
|
528,300
|
|
Cancers of
epithelia: carcinomas
|
992,700
|
(85%)
|
417,175
|
(79%)
|
Oral cavity
and pharynx
|
29,800
|
(3%)
|
7,700
|
(1%)
|
Digestive
organs (total)
|
236,900
|
(20%)
|
120,325
|
(23%)
|
Colon and rectum
|
152,000
|
(13%)
|
57,000
|
(11%)
|
Pancreas
|
27,700
|
(2%)
|
25,000
|
(5%)
|
Stomach
|
24,000
|
(2%)
|
13,600
|
(3%)
|
Liver and
biliary system
|
15,800
|
(1%)
|
12,600
|
(2%)
|
Respiratory
system (total)
|
187,100
|
(16%)
|
154,200
|
(29%)
|
Lung
|
170,000
|
(15%)
|
149,000
|
(28%)
|
Breast
|
183,000
|
(16%)
|
46,300
|
(9%)
|
Skin (total)
|
(>700,000)*
|
|
9,100
|
(2%)
|
Malignant
melanoma
|
32,000
|
(3%)
|
6,800
|
(1%)
|
Reproductive
tract (total)
|
244,400
|
(21%)
|
59,950
|
(11%)
|
Prostate gland
|
165,000
|
(14%)
|
35,000
|
(7%)
|
Ovary
|
22,000
|
(2%)
|
13,300
|
(3%)
|
" Uterine
cervix
|
13,500
|
(1%)
|
4,400
|
(1%)
|
Uterus
(endornetrium)
|
31,000
|
(3%)
|
5,700
|
(1%)
|
Urinary organs
(total)
|
79,500
|
(7%)
|
20,800
|
(4%)
|
Bladder
|
52,300
|
(4%)
|
9,900
|
(2%)
|
Cancers of the
hemopoietic and immune system: leukemias and lymphomas
|
93,000
|
(8%)
|
50,000
|
(9%)
|
Cancers of
central nervous system and eye: gliomas, retinoblastoma, etc.
|
18,250
|
(2%)
|
12,350
|
(2%)
|
Cancers of
connective tissues, muscles,
|
|
|
|
|
and
vasculature: sarcomas
|
8,000
|
(1%)
|
4,150
|
(1%)
|
All other
cancers + unspecified sites
|
57,050
|
(5%)
|
43,425
|
(8%)
|
'Nonmelanoma
skin cancers are not included in total of all cancers, since almost all are
cured easily and many go unrecorded.
In the world as
a whole, the five most common cancers are those of the lung, stomach, breast,
colon/rectum, and uterine cervix, and the total number of new cancer cases per
year is just over 6 million. Note that only about half the number of people who
develop cancer die of it. (Data for USA from American Cancer Society, Cancer
Facts and Figures, 1993.)
the
corresponding type of malignant tumor being an adenocarcinoma (Figure
24-2); a chondroma and a chondrosarcoma are, respectively, benign
and malignant tumors of cartilage. About 90% of human cancers are carcinomas,
perhaps because most of the cell proliferation in the body occurs in epithelia
or perhaps because epithelial tissues are most frequently exposed to the
various forms of physical and chemical damage that favor the development of
cancer.
Each cancer has
characteristics that reflect its origin. Thus, for example, the cells of an
epidermal basal-cell carcinoma, derived from a keratinocyte stem cell in
the skin, will generally continue to synthesize cytokeratin intermediate filaments,
whereas the cells of a melanoma, derived from a pigment cell in the
skin, will often (but not always) continue to make pigment granules. Cancers
originating from different cell types are, in general, very different
diseases. The basal-cell carcinoma, for example, is only locally invasive and
rarely forms metastases, whereas the melanoma is much more malignant and
rapidly gives rise to many metastases (behavior that recalls the migratory
tendencies of the normal pigment-cell precursors during development, discussed
in Chapter 21). The basal-cell carcinoma is usually easy to remove by surgery,
leading to complete cure; but the malignant melanoma, once it has metastasized,
is often impossible to extirpate and consequently fatal.
Cancer as a
Microevolutionary Process
This hastens
evolution of the complex set of properties required for neoplasia and
malignancy and helps the cancer cells develop resistance to anticancer drugs.
At the same time, however, defects ofDNA metabolism underlying such mutability
may make the cancer cells uniquely vulnerable to a suitably designed
therapeutic attack.
The Molecular
Genetics of Cancer 15
Because cancer is the outcome of a series of random genetic
accidents subject to natural selection, no two cases even of the same variety
of the disease are likely to be genetically identical. Nevertheless, all
cancers can be expected to involve a disruption of the normal restraints on
cell proliferation, and for each cell type there is a finite number of ways in
which such disruption can occur. In fact, changes in a relatively small set of
genes appear to be responsible for much of the derangement of cell behavior in
cancer. The identification and characteriza tion of many of these genes has
been one of the great triumphs of molecular biology.
Cell proliferation can be regulated directly or indirectly —
directly through the mechanism that determines whether a cell passes the
restriction point, or "Start," of the cell-division cycle, as
discussed in Chapter 17; or indirectly, for example, through regulation of the
commitment to terminal differentiation or programmed cell death. In either case
the normal regulatory genes can be loosely classified into those whose
products help stimulate an increase in cell numbers and those whose products
help inhibit it. Correspondingly, there are two mutational routes toward the
uncontrolled cell proliferation and invasiveness that are characteristic of
cancer. 'The first is to make a
stimulatory gene hyperactive: this type of mutation has a dominant effect —
only one of the cell's two gene copies need undergo the change — and the
altered gene is called an oncogene (the normal allele being a proto-oncogene;
from Greek onkos, a tumor). The second is to K make an inhibitory
gene inactive: this type of mutation usually has a recessive effect — both the
cell's gene copies must be inactivated or deleted to free the cell of the
inhibition — and the lost gene is called, for want of a better term, a tumor
suppressor gene.
The mutant genes
with a dominant effect — that is, the oncogenes — can be identified directly by
taking DNA from the tumor cells and searching for fragments of it that, when
introduced into normal cells, will cause these cells to behave like tumor
cells. Techniques for achieving this feat were first devised in the late 1970s;
their development followed earlier studies of a very similar process that
occurs naturally, when viruses move their genetic material from cell to cell. |
This work paved the way for an explosion of discoveries of oncogenes and proto-4
oncogenes. More recently, progress has been made in the more difficult task
of identifying and cloning tumor suppressor genes.
In this section
we discuss oncogenes and tumor suppressor genes in turn. We conclude by
presenting a case study of one common variety of cancer, where the steps of
tumor progression can be related to a series of identified mutations.
Retroviruses
Can
Act as Vectors for Oncogenes That Transform Cell Behavior 16> 17>
18
Viruses have
played a remarkable part in the search for the genetic causes of human cancer.
Although viruses have no role in the majority of common human cancers, they are
more prominent as causes of cancer in some animal species, and analysis of
animal tumor viruses has provided a key to the mechanisms of cancer in general.
The first animal
tumor virus was discovered more than 80 years ago in chickens, which are
subject to infections that cause connective-tissue tumors, or sarcomas. The
infectious agent was characterized as a virus — the Rons sarcoma virus,
The Molecular
Genetics of Cancer 1273
1 Some Changes
Commonly Observed When a Normal Tissue-Culture Cell Is transformed by a Tumor Virus
1. Plasma-membrane-related
abnormalities
A.
Enhanced transport of metabolites
B.
Excessive bleeding of plasma membrane
C.
Increased mobility of plasma membrane
proteins
2. Adherence
abnormalities
A.
Diminished adhesion to surfaces: therefore
able to maintain a rounded
morphology
B.
Failure of actin filaments to organize into
stress fibers C. Reduced external coat
of fibronectin D. High production of
plasminogen activator, causing increased extracellular
proteoiysis
3. Growth
and division abnormalities
A. Growth to an
unusually high cell density. B. Lowered
requirement for growth factors. C. Less anchorage dependence (can grow even
without attachment to rigid surface). D. "Immortal" (can continue
proliferating indefinitely). E. Can
cause tumors when injected into susceptible animals which we now know to be an
RNA virus. Like all the other RNA tumor viruses discovered since, it is a
retrovirus. When it infects a cell, its RNA is copied into DNA by reverse
transcription and the DNA is inserted into the host genome, where it can
persist and be inherited by subsequent generations of cells. Figure 6-82
outlines the life cycle of a retrovirus and shows how its genome undergoes
reverse transcription, integration into host DNA, and exit from and entry into
host cells.
"But how does the viral infection cause tumors? The solution
to this problem, as to so many others in cell biology, depended on the
development of a convenient assay by which different strains of virus could be
rapidly tested for their tumor-causing capacity. The assay system, still widely
used, consists simply of fibroblasl cells proliferating in a culture dish. If
active tumor virus is added to the culture medium, small colonies of abnormally
proliferating transformed cells appear within a few days. Each such colony is a
clone derived from a single cell that has been infected with the virus and has
stably incorporated the viral genetic material. Released from the social
controls on cell division, the transformed cells outgrow normal ones in the
culture dish just as in the body and are therefore usually easy to select. The
transformed cells commonly show a complex syndrome of abnormalities
(summarized in Table 24-3). They tend not to be constrained by
density-dependent inhibition of cell division (see Figure 17-39), for example,
but pile up in layer upon layer as they proliferate (Figure 24-21). In
addition, they often do not depend on anchorage for growth and are capable of
comaci-inhibited monolayer of normal cells
growth medium multilayer of uninhibited cancer cells.
Loss of contact inhibition. Canter cells,
unlike ™f» normal cells, usually continue 10 fi'»" and pile up on
top of one another after they have formed a confluent monolayer.
plastic tissue-culture dish dividing even when held in suspension; they have an altered
shape and adhere poorly to the substratum and to other cells, maintaining a
rounded appearance reminiscent of a normal cell in mitosis; they may be able to
proliferate even in the absence of growth factors; they are immortal and do not
undergo senescence in culture; and when they are injected back into a suitable
host animal, they can give rise to tumors.
The misbehavior
of the transformed cells can be traced to an oncogene dial is carried by the
virus but is not necessary for the virus's own survival or reproduction. This
was first demonstrated by the discovery of mutant Rous sarcoma viruses that
multiply normally but no longer transform their host cells. The loss of
transforming ability could be shown to correspond to loss or inactivation of a
particular gene, which was given the name sir (Figure 24-22). This specific
gene in the Rous sarcoma virus is responsible for cell transformation in
vitro and for tumor formation in vivo, but it is unnecessary baggage
from the point of view of the virus's own propagation.
Retroviruses
Pick Up Oncogenes by AccidentI6'17> l9
If the viral src gene is bad for the animal and unnecessary
to the virus, why is it present and where does it come from? When a radioactive
DNA copy of the viral src gene sequence was used as a probe to search
for related sequences by DNA-DNA hybridization, it was found that the genomes
of normal vertebrate cells contain a sequence that is closely similar, but not
identical, to the src gene of the Rous sarcoma virus. This normal
cellular counterpart of the viral src gene (v-src) is called c-src {or
just src). It is the proto-oncogene corresponding to the oncogene v-src.
Evidently, the gene has been picked up accidentally by the retrovirus from
the genome of a previous host cell but has undergone mutation in the process
(Figure 24-23). The result is a perturbed gene function that leads to cancer
and so brings the gene, and the virus that carries it, to the scientist's
attention. The retrovirus has, in effect, cloned the gene for us. A large
number of other oncogenes have been identified in other retroviruses and
analyzed in similar ways (Table 24-4]. Each has led to the discovery of a
corresponding proto-oncogene that is present in every normal cell.
A Retrovirus
Can
Transform
a Host Cell by Inserting Its DNA Next to a Proto-oncogene of the Host20
There are two ways in which a proto-oncogene can be converted into
an oncogene upon incorporation into a retrovirus: the gene sequence may be
altered
figure 24-22
Cell
transformation by the Rous sarcoma virus. The
scanning electron
micrographs show cells in culture infected with a form of the Rous sarcoma
virus that carries a temperature-sensitive mutation in the gene responsible Tor
transformation (the v-src oncogene). (A) The cells are transformed and have an
abnormal rounded shape at low temperature (34°C), where the oncogene product is
functional. IB) The same cells adhere strongly to the culture dish and thereby
regain their normal flattened appearance when the oncogene product is
inactivated by a shift to higher temperature (39"C). (Courtesy of G.
Steven Martin.)
The Molecular
Genetics of Cancer
p.
1275
murine leukemia virus terminal repeats Cap-C
939pol
Rous sarcoma virus
CapH__L 5'
(A) host cell DNA pol intron region encoding kinase domain chicken c-src proto-oncogene
(B)
Table 24-4 Some
Oncogenes Originally Identified Through Their Presence in Transforming
Retroviruses
Oncogene
Proto-oncogene Function Source of Virus Virus-induced Tumor
abl
|
protein kinase
(tyrosine)
|
mouse cat
|
pre-B-cell
leukemia sarcoma
|
erb-B
|
protein kinase
(tyrosine):
|
chicken
|
erythroleukemia,
|
epidermal growth
factor (EGF) receptor
fes
protein kinase (tyrosine)
cat/chicken
fins
protein kinase (tyrosine): cat
macrophage colony-stimulating factor (M-CSF) receptor
fps
\ products associate to form mouse jun j
AP-1 gene regulatory protein
chicken
kit
protein kinase (tyrosine): cat
Steel factor receptor
raf
protein kinase (serine/threonine)
chicken/ activated by Ras mouse
myc
gene regulatory protein of chicken the
HLH family
H-ras
GTP-binding protein rat K-ras GTP-binding protein
rat
rel
gene regulatory protein
related turkey to NFKB
sis
platelet-derived growth
factor, monkey B chain
src
protein kinase (tyrosine) chicken
fibrosarcoma, sarcoma sarcoma, osteosarcoma
fibrosarcoma, sarcoma sarcoma
sarcoma;
myelocytoma, carcinoma sarcoma; erythroleukemia sarcoma; erythroleukemia
reticuloendotheliosis sarcoma sarcoma
The structure of the Rous
sarcoma virus. (A) The organization of the viral genome as compared with that
of a more typical retrovirus (murine leukemia virus). Rous sarcoma virus is
unusual among the retroviruses that carry oncogenes in that it has retained all
the three viral genes required for the ordinary viral life cycle: gag (which
produces a polyprotein that is cleaved to generate the capsid proteins), pol
(which produces reverse transcriptase and an enzyme involved in integrating
the viral chromosome into the host genome), and env (which produces the
envelope glycoprotein). In other oncogenic retroviruses one or more of these
viral genes are wholly or partly lost in exchange for the acquisition of the
transforming oncogene, and therefore infectious particles of the transforming
virus can be generated only in a cell that is simultaneously infected with a
nondefective, nontransforming helper virus, which supplies the missing
functions. (Often the transforming oncogene is fused to a residual fragment of
gag, leading to production of a hybrid oncogenic protein that includes part of
the Gag sequence.) (B) The relationship between the v-src oncogene and
the cellular src proto-oncogene from which it has been derived. The introns
present in cellular src have been spliced out of v-src; in addition, v-src
contains mutations that alter the amino acid sequence of the protein, making it
hyperactive and unregulated as a tyrosine-specific protein kinase. Rous sarcoma
virus has been highly selected (by cancer research workers) for its ability to
transform cells to neoplasia, and it does this with unusual speed and
efficiency.
p. 1276